🏭 The expansion will include eight 20,000-liter mammalian cell culture bioreactors, adding to the already planned eight bioreactors.
💼 The project is part of Fujifilm Diosynth’s strategy to build out large-scale production capacity in the US and Europe.
🌍 The company considered expanding in Europe and other regions, but concluded that growing the Holly Springs site was the best option.
📈 The expansion is projected to add 680 more jobs, bringing the total to over 1,400 jobs.
Introduction:
Fujifilm Diosynth Biotechnologies is expanding its end-to-end biomanufacturing facility in Holly Springs, NC, with an additional $1.2 billion investment. The expansion will include the addition of eight 20,000-liter mammalian cell culture bioreactors by 2028. This investment comes after the company experienced increased demand from clients and considered expanding in other regions before deciding on Holly Springs.
- Fujifilm Diosynth considered expanding in other regions before deciding to expand in Holly Springs.
- The expansion will include the addition of eight 20,000-liter mammalian cell culture bioreactors.
- Holly Springs will become one of the largest cell culture biopharmaceutical CDMO facilities in North America.
- The expansion is part of Fujifilm Diosynth’s “Partners for Life” strategy to enhance the resiliency of its supply chain.
- The company is capable of quickly moving between facilities in Holly Springs and Denmark.
Conclusion:
Fujifilm Diosynth Biotechnologies is investing $1.2 billion to expand its biomanufacturing facility in Holly Springs, NC. The expansion will increase the company’s manufacturing capacity and create additional jobs. This investment is part of the company’s strategy to enhance its supply chain and meet the growing demand for outsourced manufacturing services in the biopharmaceutical industry.
